FDA grants approval for Amylyx’s Relyvrio to treat ALS
Pharmaceutical Technology
OCTOBER 1, 2022
The US Food and Drug Administration (FDA) has granted approval for Amylyx Pharmaceuticals’ Relyvrio (sodium phenylbutyrate and taurursodiol) to treat adult patients with amyotrophic lateral sclerosis (ALS). A progressive and fatal neurodegenerative ailment, ALS is caused by the death of motor neurons in the brain and spinal cord.
Let's personalize your content